Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Pancreatic Neoplasms × vandetanib × Clear all

Phase

Phase 1 2 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 11 Lung Neoplasms 7 Neoplasm Metastasis 6 Breast Neoplasms 5 Thyroid Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Prostatic Neoplasms 3 Urinary Bladder Neoplasms 2 Ovarian Neoplasms 2 Neoplasms 2 Kidney Neoplasms 2 Fallopian Tube Neoplasms 2 Carcinoma, Renal Cell 2 Carcinoma, Medullary 2 Urethral Neoplasms 1 Ureteral Neoplasms 1 Thyroid cancer, medullary 1 Thyroid Diseases 1 Thyroid Cancer, Papillary 1 Small Cell Lung Carcinoma 1 Relapsed Pediatric Solid Tumor 1 Recurrence 1 Rectal Neoplasms 1 Precancerous Conditions 1 Pleural Effusion 1 Peritoneal Neoplasms 1 Pancreatic Neoplasms 1 Oligodendroglioma 1 Non-small Cell Lung Cancer Metastatic 1 Multiple Myeloma 1

Interventions

Gemcitabine 268 Fluorouracil 72 Oxaliplatin 70 130-nm albumin-bound paclitaxel 59 Leucovorin 51 Capecitabine 48 Radiotherapy 47 Albumin-Bound Paclitaxel 47 Irinotecan 41 Cisplatin 34 Taxes 32 Erlotinib Hydrochloride 32 pembrolizumab 26 Radiosurgery 26 Docetaxel 25 S 1 (combination) 24 Bevacizumab 21 folfirinox 18 Nivolumab 17 Radiation 15 Magnetic Resonance Spectroscopy 15 Cyclophosphamide 15 Cetuximab 15 irinotecan sucrosofate 14 Drug Therapy 12 Surgical Procedures, Operative 11 Specimen Handling 10 Biopsy 10 Paclitaxel 9 Ipilimumab 9

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01601808 2025-03-13

ViP

University of Liverpool

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡